CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, regulatory and financial factors. Read more here.

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

CVS released a statement to News 8 and provided more details on its investments, colleague support initiatives, and the acquisition of Rite Aid prescription files.

An exclusive on-the-record dialogue with NMA officers, Raheem DeVaughn, and Gilead experts exploring stigma and barriers around HIV in Black communities.

Bridging the Gap: Gilead’s Work to Help End the HIV Epidemic How Gilead is helping innovate HIV prevention, removing stigma and empowering Black women.

CVS has a timeline for rebranding 49 Rite Aid and Bartell Drugs stores it is buying from bankrupt Rite Aid. But prospects for another 61 stores are uncertain.

Foster City pharmaceuticals giant Gilead Sciences has agreed to pay a $202 million settlement over allegations in a lawsuit by state and federal authorities that it paid doctors kickbacks, sent ...